ClinicalTrials.gg
CompletedNCT05906628Updated Jul 31, 2025Results posted

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

A Phase 2 interventional study of Ruxolitinib cream and Vehicle in Hand Eczema, sponsored by Incyte Corporation. Completed at 36 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Eczema by Incyte Corporation — 2 open to participants now, 2 under way, none of them phase 3. Eczema · Incyte Corporation.

Started
2023
with 4 others
Phase 2
2 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Eczema by Incyte Corporation, this one is one of 5 that started in 2023, is one of 2 in phase 2, and was the 7th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

2 of the 10 studies in Eczema by Incyte Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Eczema by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

03

Conditions studied

  • Hand Eczema

Keywords

  • eczema
  • chronic hand eczema (CHE)
  • dermatitis
  • skin disease
  • JAK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CHE for at least 6 months prior to screening. Diagnosis of chromic hand eczema (CHE) as defined by hand eczema (HE) lasting > 3 months or ≥ 2 flares within the previous 12 months.
  • Screening and baseline IGA-CHE 3 or 4.
  • Baseline CHE-related Itch NRS ≥ 4.
  • Have been treated with at least 1 prescription CHE therapy or if such therapy was not advisable or .
  • Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Known triggers for CHE (allergic or irritant, such as those identified by previous patch tests) cannot be avoided during the course of this study.
  • Any serious illness or medical, physical, or psychiatric condition(s).
  • Laboratory values outside of the protocol-defined criteria.
  • Use of protocol-defined treatments within the indicated before baseline.
  • Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks before baseline.
  • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.

    Drug: Ruxolitinib cream

  • Placebo comparator
    Vehicle

    Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.

    Drug: Vehicle

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB18424 cream

  • DrugVehicle

    Vehicle cream is a topical formulation applied as a thin film to affected areas.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16

    The Investigator's Global Assessment-Chronic Hand Eczema (IGA-CHE) is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.

    Time frame: Baseline; Week 16

Secondary outcomes

  1. Percentage of Participants Achieving ITCH4 Response at Weeks 4 and 16

    ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).

    Time frame: Baseline; Weeks 4 and 16

  2. Percentage of Participants Achieving ITCH4 Response at Day 3 and Week 1 (Day 7)

    ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).

    Time frame: Baseline; Day 3; Week 1 (Day 7)

  3. Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Each Post-Baseline Visit

    The IGA-CHE is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.

    Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 24, and 32

  4. Change From Baseline in CHE-related Itch NRS Score at Each Post-Baseline Visit

    The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 1-32

  5. Time to ≥4-point Improvement From Baseline in CHE-related Itch NRS Score

    ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).

    Time frame: Baseline; up to Week 32

  6. Change From Baseline in CHE-related Pain NRS Score at Each Post-Baseline Visit

    The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; Weeks 1-32

  7. Percentage of Participants Achieving ≥2-point Improvement in CHE-related Skin Pain NRS Score From Baseline to Week 16

    The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).

    Time frame: Baseline; up to Week 16

  8. Time to ≥2-point Improvement From Baseline in CHE-related Skin Pain NRS Score

    The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).

    Time frame: Baseline; up to Week 32

  9. Percentage Change in Hand Eczema Severity Index (HECSI) Score From Baseline to Week 16

    The HECSI divides the hand into 5 areas for assessment (fingertips, fingers \[except the tips\], palms, back of hands, and wrists). Each of the 5 areas of the hand are assessed separately for erythema, induration/papulation, vesicles, fissuring, scaling, and edema using the following scale: 0, no skin changes; 1, mild disease; 2, moderate disease; and 3, severe disease. To determine the HECSI score, the affected area for each location (total of both hands) is given a score from 0 to 4 (0, 0%; 1, 1%-25%; 2, 26%-50%; 3, 51%-75%; and 4, 76%-100%) based on the extent of clinical symptoms. Finally, the score given for the extent at each location is multiplied by the total sum of the intensity of each clinical feature to calculate the total HECSI score, varying from 0 to a maximum severity score of 360 points. Percentage change was calculated as the (\[post-Baseline value minus the Baseline value\]/\[Baseline value\]) \* 100.

    Time frame: Baseline; up to Week 16

  10. Patient Global Impression of Change (PGIC) Score at Each Post-Baseline Visit

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE. Participants were asked to select 1 response from the response options that best described the overall change in their CHE since they started study treatment: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse, and 7, very much worse.

    Time frame: Baseline; up to Week 32

  11. Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Weeks 2, 4, 8, 12, 16, 24, and 32

    The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. The questionnaire was analyzed under 6 subscales as follows: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); and treatment (Question 10). Scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0 (Question 7: "Prevented work or studying" = Yes = 3). The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.

    Time frame: Baseline; up to Week 32

  12. Number of Participants With the Indicated EQ-5D-5L Dimension Scores at Weeks 2, 4, 8, 12, 16, 24, and 32

    The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score).

    Time frame: Baseline; up to Week 32

  13. Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score at Weeks 2, 4, 8, 12, 16, 24, and 32

    The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 32

  14. Change From Baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up

    The QOLHEQ is a validated disease-specific instrument to assess disease-specific health-related quality of life in participants suffering from CHE over the past 7 days. It consists of 30 items that are summarized according to impairments for 4 subscales: symptoms, emotions, limitations in functioning, and treatment and prevention. Each item is scored on a scale of never, rarely, sometimes, often, and all the time. The overall score is calculated by summing all items and ranges from 0 to 117. Higher scores indicate a greater impact on quality of life. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 36

  15. Change From Baseline in Work Productivity and Activity Impairment Questionnaire v2.0 in Chronic Hand Dermatitis (WPAI-ChHD) Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up

    The WPAI-ChHD questionnaire is a patient-reported quantitative assessment of the amount of absenteeism (measured as percentage of work time missed \[PWTM\] due to CHE), presentism, and daily activity impairment (percentage of impairment while working \[PIWW\] due to CHE, percentage of overall work impairment \[POWI\] due to CHE, percentage of activity impairment \[PAI\] due to CHE) attributable to a specific health problem. The WPAI-ChHD is a 6-item questionnaire used to assess the impact of chronic hand dermatitis (ChHD, the same as CHE in this context) on job performance and productivity in the last 7 days. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Scores range from 0% (no impairment) to 100% (complete impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 36

  16. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) in the DBVC Period

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.

    Time frame: up to Week 16

  17. Number of Participants With Any ≥Grade 3 TEAE in the DBVC Period

    A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Week 16

  18. Number of Participants With Any TEAE in the OLE Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.

    Time frame: up to Week 36

  19. Number of Participants With Any ≥Grade 3 TEAE in the OLE Period

    A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Week 36

  20. Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the DBVC Period

    The investigator determined whether a change was clinically meaningful.

    Time frame: up to Week 16

  21. Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the OLE Period

    The investigator determined whether a change was clinically meaningful.

    Time frame: up to Week 36

07

Results

Posted Jul 31, 2025

Participant flow

16-Week DBVC Period
Participant flow — 16-Week DBVC Period
MilestoneRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Started9492
Completed8477
Not completed1015
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up21
Withdrew: Protocol violation42
Withdrew: Withdrawal by subject411
16-Week OLE Period
Participant flow — 16-Week OLE Period
MilestoneRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Started8477
Completed7671
Not completed86
Withdrew: Death10
Withdrew: Lost to follow-up11
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject64

Outcome measures

PrimaryPercentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16

The Investigator's Global Assessment-Chronic Hand Eczema (IGA-CHE) is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16
percentage of participantsRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 1653.2 (42.6 to 63.6)10.9 (5.3 to 19.1)
Statistical analysis
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 9.82 · 95% CI 4.48 to 21.49Cochran-Mantel-Haenszel test was stratified by stratification factors IGA-CHE score (3 or 4) and region (North America or outside of North America).
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Response rate difference: 42.5 · 95% CI 30.70 to 54.36
SecondaryPercentage of Participants Achieving ITCH4 Response at Weeks 4 and 16

ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).

Time frame:
Baseline; Weeks 4 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ITCH4 Response at Weeks 4 and 16
percentage of participantsRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Week 446.7 (36.3 to 57.4)17.6 (10.4 to 27.0)
Week 1652.2 (41.5 to 62.7)23.1 (14.9 to 33.1)
Statistical analysis
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.23 · 95% CI 2.14 to 8.38Cochran-Mantel-Haenszel test was stratified by stratification factors IGA-CHE score (3 or 4) and region (North America or outside of North America).
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Response rate difference: 29.5 · 95% CI 16.69 to 42.24
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.90 · 95% CI 2.02 to 7.51Cochran-Mantel-Haenszel test was stratified by stratification factors IGA-CHE score (3 or 4) and region (North America or outside of North America).
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Response rate difference: 29.5 · 95% CI 16.34 to 42.57
SecondaryPercentage of Participants Achieving ITCH4 Response at Day 3 and Week 1 (Day 7)

ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).

Time frame:
Baseline; Day 3; Week 1 (Day 7)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ITCH4 Response at Day 3 and Week 1 (Day 7)
percentage of participantsRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Day 312.9 (6.6 to 22.0)6.0 (2.0 to 13.5)
Week 1 (Day 7)28.0 (18.7 to 39.1)9.5 (4.2 to 17.9)
Statistical analysis
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Cochran-Mantel-Haenszel · p = 0.1789 · Odds ratio (or): 2.06 · 95% CI 0.718 to 5.923Cochran-Mantel-Haenszel test was stratified by stratification factors IGA-CHE score (3 or 4) and region (North America or outside of North America).
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Cochran-Mantel-Haenszel · p = 0.0024 · Odds ratio (or): 3.79 · 95% CI 1.603 to 8.951Cochran-Mantel-Haenszel test was stratified by stratification factors IGA-CHE score (3 or 4) and region (North America or outside of North America).
SecondaryPercentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Each Post-Baseline Visit

The IGA-CHE is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.

Time frame:
Baseline; Weeks 2, 4, 8, 12, 16, 24, and 32
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Week 222.5 (14.3 to 32.6)1.2 (0.0 to 6.3)
Week 437.8 (27.8 to 48.6)4.8 (1.3 to 11.7)
Week 844.3 (33.7 to 55.3)3.8 (0.8 to 10.6)
Week 1252.9 (41.9 to 63.7)14.1 (7.3 to 23.8)
Week 1658.1 (47.0 to 68.7)12.8 (6.3 to 22.3)
Week 2451.2 (39.9 to 62.4)51.4 (39.4 to 63.1)
Week 3252.6 (40.9 to 64.0)54.8 (42.7 to 66.5)
Statistical analysis
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 9.91 · 95% CI 4.44 to 22.13Cochran-Mantel-Haenszel test was stratified by stratification factors IGA-CHE score (3 or 4) and region (North America or outside of North America).
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Response rate difference: 45.6 · 95% CI 32.83 to 58.27
SecondaryChange From Baseline in CHE-related Itch NRS Score at Each Post-Baseline Visit

The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 1-32
Reported as:
Mean · scores on a scale
Change From Baseline in CHE-related Itch NRS Score at Each Post-Baseline Visit
scores on a scaleRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Baseline6.68 ± 1.6196.63 ± 1.592
Change from Baseline at Week 2-3.03 ± 2.346-1.34 ± 1.725
Change from Baseline at Week 4-3.88 ± 2.275-2.02 ± 2.062
Change from Baseline at Week 8-4.23 ± 2.437-2.20 ± 2.353
Change from Baseline at Week 12-4.41 ± 2.315-2.51 ± 2.350
Change from Baseline at Week 16-4.24 ± 2.279-2.47 ± 2.226
Change from Baseline at Week 24-4.23 ± 2.400-4.85 ± 2.323
Change from Baseline at Week 32-4.41 ± 2.163-5.01 ± 2.095
SecondaryTime to ≥4-point Improvement From Baseline in CHE-related Itch NRS Score

ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).

Time frame:
Baseline; up to Week 32
Reported as:
Median · days
Time to ≥4-point Improvement From Baseline in CHE-related Itch NRS Score
daysRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Time to ≥4-point Improvement From Baseline in CHE-related Itch NRS Score15.0 (12.0 to 18.0)29.0 (17.0 to 73.0)
Statistical analysis
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Log Rank · p = 0.0025 · Cox regression model: 1.719 · 95% CI 1.211 to 2.440Cox regression model stratified by stratification factors (Baseline IGA-CHE 3/4, Region : North America or outside of North America) was conducted to compare the difference in hazard rate between treatment and vehicle.
SecondaryChange From Baseline in CHE-related Pain NRS Score at Each Post-Baseline Visit

The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; Weeks 1-32
Reported as:
Mean · scores on a scale
Change From Baseline in CHE-related Pain NRS Score at Each Post-Baseline Visit
scores on a scaleRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Baseline6.14 ± 2.1646.06 ± 1.754
Change from Baseline at Week 2-2.86 ± 2.433-1.27 ± 1.671
Change from Baseline at Week 4-3.82 ± 2.435-1.83 ± 1.929
Change from Baseline at Week 8-4.15 ± 2.625-1.95 ± 2.118
Change from Baseline at Week 12-4.25 ± 2.415-2.21 ± 2.206
Change from Baseline at Week 16-4.23 ± 2.627-2.32 ± 2.036
Change from Baseline at Week 24-4.25 ± 2.584-4.47 ± 2.261
Change from Baseline at Week 32-4.37 ± 2.524-4.61 ± 2.112
SecondaryPercentage of Participants Achieving ≥2-point Improvement in CHE-related Skin Pain NRS Score From Baseline to Week 16

The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).

Time frame:
Baseline; up to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥2-point Improvement in CHE-related Skin Pain NRS Score From Baseline to Week 16
percentage of participantsRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Week 259.0 (47.693 to 69.715)34.1 (24.027 to 45.449)
Week 476.7 (66.394 to 85.179)47.5 (36.213 to 58.977)
Week 874.4 (63.555 to 83.396)52.0 (40.151 to 63.686)
Week 1284.0 (73.719 to 91.450)53.5 (41.287 to 65.452)
Week 1681.9 (71.106 to 90.021)58.6 (46.166 to 70.228)
Week 2483.3 (72.133 to 91.375)90.2 (79.810 to 96.304)
Week 3286.8 (76.356 to 93.765)88.3 (77.428 to 95.179)
SecondaryTime to ≥2-point Improvement From Baseline in CHE-related Skin Pain NRS Score

The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).

Time frame:
Baseline; up to Week 32
Reported as:
Median · days
Time to ≥2-point Improvement From Baseline in CHE-related Skin Pain NRS Score
daysRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Time to ≥2-point Improvement From Baseline in CHE-related Skin Pain NRS Score5.0 (4.0 to 7.0)8.0 (5.0 to 12.0)
Statistical analysis
  • Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID to Ruxolitinib 1.5% Cream BID · Log Rank · p = 0.1319 · Cox regression model: 1.279 · 95% CI 0.931 to 1.759Cox regression model stratified by stratification factors (Baseline IGA-CHE 3/4, Region : North America or outside of North America) was conducted to compare the difference in hazard rate between treatment and vehicle.
SecondaryPercentage Change in Hand Eczema Severity Index (HECSI) Score From Baseline to Week 16

The HECSI divides the hand into 5 areas for assessment (fingertips, fingers \[except the tips\], palms, back of hands, and wrists). Each of the 5 areas of the hand are assessed separately for erythema, induration/papulation, vesicles, fissuring, scaling, and edema using the following scale: 0, no skin changes; 1, mild disease; 2, moderate disease; and 3, severe disease. To determine the HECSI score, the affected area for each location (total of both hands) is given a score from 0 to 4 (0, 0%; 1, 1%-25%; 2, 26%-50%; 3, 51%-75%; and 4, 76%-100%) based on the extent of clinical symptoms. Finally, the score given for the extent at each location is multiplied by the total sum of the intensity of each clinical feature to calculate the total HECSI score, varying from 0 to a maximum severity score of 360 points. Percentage change was calculated as the (\[post-Baseline value minus the Baseline value\]/\[Baseline value\]) \* 100.

Time frame:
Baseline; up to Week 16
Reported as:
Mean · percentage change
Percentage Change in Hand Eczema Severity Index (HECSI) Score From Baseline to Week 16
percentage changeRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Week 2-54.93 ± 34.148-16.68 ± 50.066
Week 4-69.58 ± 37.852-26.00 ± 58.790
Week 8-77.25 ± 29.583-33.81 ± 62.468
Week 12-78.65 ± 37.390-41.00 ± 50.605
Week 16-84.88 ± 22.971-37.61 ± 54.760
SecondaryPatient Global Impression of Change (PGIC) Score at Each Post-Baseline Visit

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE. Participants were asked to select 1 response from the response options that best described the overall change in their CHE since they started study treatment: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse, and 7, very much worse.

Time frame:
Baseline; up to Week 32
Reported as:
Mean · scores on a scale
Patient Global Impression of Change (PGIC) Score at Each Post-Baseline Visit
scores on a scaleRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Week 21.85 ± 0.8243.21 ± 1.309
Week 41.74 ± 0.8973.09 ± 1.288
Week 81.64 ± 0.7843.04 ± 1.344
Week 121.60 ± 0.8513.04 ± 1.399
Week 161.61 ± 0.8933.00 ± 1.308
Week 241.61 ± 0.7501.73 ± 0.931
Week 321.57 ± 0.9321.67 ± 0.877
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score at Weeks 2, 4, 8, 12, 16, 24, and 32

The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. The questionnaire was analyzed under 6 subscales as follows: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); and treatment (Question 10). Scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0 (Question 7: "Prevented work or studying" = Yes = 3). The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.

Time frame:
Baseline; up to Week 32
Reported as:
Mean · scores on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Weeks 2, 4, 8, 12, 16, 24, and 32
scores on a scaleRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Baseline13.17 ± 6.27711.84 ± 5.896
Change from Baseline at Week 2-7.95 ± 5.046-3.62 ± 4.065
Change from Baseline at Week 4-8.68 ± 5.517-4.78 ± 5.116
Change from Baseline at Week 8-9.11 ± 5.837-5.32 ± 4.977
Change from Baseline at Week 12-9.38 ± 5.905-5.88 ± 5.964
Change from Baseline at Week 16-9.62 ± 6.055-5.36 ± 5.441
Change from Baseline at Week 24-8.97 ± 6.457-8.71 ± 5.517
Change from Baseline at Week 32-9.71 ± 5.675-9.34 ± 5.550
SecondaryNumber of Participants With the Indicated EQ-5D-5L Dimension Scores at Weeks 2, 4, 8, 12, 16, 24, and 32

The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score).

Time frame:
Baseline; up to Week 32
Reported as:
Count of participants · Participants
Number of Participants With the Indicated EQ-5D-5L Dimension Scores at Weeks 2, 4, 8, 12, 16, 24, and 32
ParticipantsRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Mobility; Baseline, Level 17073
Mobility; Baseline, Level 2148
Mobility; Baseline, Level 356
Mobility; Baseline, Level 401
Mobility; Baseline, Level 502
Mobility; Week 2, Level 17470
Mobility; Week 2, Level 249
Mobility; Week 2, Level 344
Mobility; Week 2, Level 421
Mobility; Week 2, Level 520
Mobility; Week 4, Level 16968
Mobility; Week 4, Level 2139
Mobility; Week 4, Level 343
Mobility; Week 4, Level 402
Mobility; Week 4, Level 500
Mobility; Week 8, Level 17170
Mobility; Week 8, Level 2145
Mobility; Week 8, Level 302
Mobility; Week 8, Level 401
Mobility; Week 8, Level 500
Mobility; Week 12, Level 16763
Mobility; Week 12, Level 279
Mobility; Week 12, Level 352
Mobility; Week 12, Level 411
Mobility; Week 12, Level 500
Mobility; Week 16, Level 16964
Mobility; Week 16, Level 279
Mobility; Week 16, Level 342
Mobility; Week 16, Level 402
Mobility; Week 16, Level 500
Mobility; Week 24, Level 16560
Mobility; Week 24, Level 268
Mobility; Week 24, Level 342
Mobility; Week 24, Level 410
Mobility; Week 24, Level 500
Mobility; Week 32, Level 16155
Mobility; Week 32, Level 257
Mobility; Week 32, Level 334
Mobility; Week 32, Level 401
Mobility; Week 32, Level 500
Self-care; Baseline, Level 15561
Self-care; Baseline, Level 22421
Self-care; Baseline, Level 356
Self-care; Baseline, Level 452
Self-care; Baseline, Level 500
Self-care; Week 2, Level 17364
Self-care; Week 2, Level 21013
Self-care; Week 2, Level 335
Self-care; Week 2, Level 401
Self-care; Week 2, Level 501
Self-care; Week 4, Level 16957
Self-care; Week 4, Level 21419
Self-care; Week 4, Level 335
Self-care; Week 4, Level 401
Self-care; Week 4, Level 500
Self-care; Week 8, Level 17657
Self-care; Week 8, Level 2615
Self-care; Week 8, Level 336
Self-care; Week 8, Level 400
Self-care; Week 8, Level 500
Self-care; Week 12, Level 17261
Self-care; Week 12, Level 2810
Self-care; Week 12, Level 304
Self-care; Week 12, Level 400
Self-care; Week 12, Level 500
Self-care; Week 16, Level 17259
Self-care; Week 16, Level 2816
Self-care; Week 16, Level 302
Self-care; Week 16, Level 400
Self-care; Week 16, Level 500
Self-care; Week 24, Level 17064
Self-care; Week 24, Level 244
Self-care; Week 24, Level 312
Self-care; Week 24, Level 410
Self-care; Week 24, Level 500
Self-care; Week 32, Level 16462
Self-care; Week 32, Level 235
Self-care; Week 32, Level 320
Self-care; Week 32, Level 400
Self-care; Week 32, Level 500
Usual activities; Baseline, Level 12538
Usual activities; Baseline, Level 23928
Usual activities; Baseline, Level 31618
Usual activities; Baseline, Level 485
Usual activities; Baseline, Level 511
Usual activities; Week 2, Level 15137
Usual activities; Week 2, Level 22732
Usual activities; Week 2, Level 3611
Usual activities; Week 2, Level 424
Usual activities; Week 2, Level 500
Usual activities; Week 4, Level 15342
Usual activities; Week 4, Level 22724
Usual activities; Week 4, Level 3614
Usual activities; Week 4, Level 402
Usual activities; Week 4, Level 500
Usual activities; Week 8, Level 16547
Usual activities; Week 8, Level 21822
Usual activities; Week 8, Level 326
Usual activities; Week 8, Level 403
Usual activities; Week 8, Level 500
Usual activities; Week 12, Level 16045
Usual activities; Week 12, Level 21726
Usual activities; Week 12, Level 331
Usual activities; Week 12, Level 403
Usual activities; Week 12, Level 500
Usual activities; Week 16, Level 16142
Usual activities; Week 16, Level 21625
Usual activities; Week 16, Level 338
Usual activities; Week 16, Level 401
Usual activities; Week 16, Level 501
Usual activities; Week 24, Level 15554
Usual activities; Week 24, Level 21813
Usual activities; Week 24, Level 323
Usual activities; Week 24, Level 410
Usual activities; Week 24, Level 500
Usual activities; Week 32, Level 15761
Usual activities; Week 32, Level 284
Usual activities; Week 32, Level 342
Usual activities; Week 32, Level 400
Usual activities; Week 32, Level 500
Pain/discomfort; Baseline, Level 135
Pain/discomfort; Baseline, Level 22828
Pain/discomfort; Baseline, Level 33736
Pain/discomfort; Baseline, Level 42019
Pain/discomfort; Baseline, Level 512
Pain/discomfort; Week 2, Level 13317
Pain/discomfort; Week 2, Level 23735
Pain/discomfort; Week 2, Level 31420
Pain/discomfort; Week 2, Level 4211
Pain/discomfort; Week 2, Level 501
Pain/discomfort; Week 4, Level 13715
Pain/discomfort; Week 4, Level 23838
Pain/discomfort; Week 4, Level 3925
Pain/discomfort; Week 4, Level 422
Pain/discomfort; Week 4, Level 502
Pain/discomfort; Week 8, Level 14622
Pain/discomfort; Week 8, Level 22936
Pain/discomfort; Week 8, Level 31013
Pain/discomfort; Week 8, Level 407
Pain/discomfort; Week 8, Level 500
Pain/discomfort; Week 12, Level 14020
Pain/discomfort; Week 12, Level 23037
Pain/discomfort; Week 12, Level 3916
Pain/discomfort; Week 12, Level 411
Pain/discomfort; Week 12, Level 501
Pain/discomfort; Week 16, Level 14220
Pain/discomfort; Week 16, Level 22838
Pain/discomfort; Week 16, Level 3614
Pain/discomfort; Week 16, Level 444
Pain/discomfort; Week 16, Level 501
Pain/discomfort; Week 24, Level 14240
Pain/discomfort; Week 24, Level 22622
Pain/discomfort; Week 24, Level 377
Pain/discomfort; Week 24, Level 401
Pain/discomfort; Week 24, Level 510
Pain/discomfort; Week 32, Level 13539
Pain/discomfort; Week 32, Level 22722
Pain/discomfort; Week 32, Level 375
Pain/discomfort; Week 32, Level 401
Pain/discomfort; Week 32, Level 500
Anxiety/depression; Baseline, Level 13941
Anxiety/depression; Baseline, Level 22828
Anxiety/depression; Baseline, Level 31611
Anxiety/depression; Baseline, Level 459
Anxiety/depression; Baseline, Level 511
Anxiety/depression; Week 2, Level 15643
Anxiety/depression; Week 2, Level 22229
Anxiety/depression; Week 2, Level 368
Anxiety/depression; Week 2, Level 423
Anxiety/depression; Week 2, Level 501
Anxiety/depression; Week 4, Level 15346
Anxiety/depression; Week 4, Level 22424
Anxiety/depression; Week 4, Level 376
Anxiety/depression; Week 4, Level 425
Anxiety/depression; Week 4, Level 501
Anxiety/depression; Week 8, Level 15746
Anxiety/depression; Week 8, Level 22324
Anxiety/depression; Week 8, Level 335
Anxiety/depression; Week 8, Level 413
Anxiety/depression; Week 8, Level 510
Anxiety/depression; Week 12, Level 15846
Anxiety/depression; Week 12, Level 21519
Anxiety/depression; Week 12, Level 357
Anxiety/depression; Week 12, Level 412
Anxiety/depression; Week 12, Level 511
Anxiety/depression; Week 16, Level 15446
Anxiety/depression; Week 16, Level 21923
Anxiety/depression; Week 16, Level 345
Anxiety/depression; Week 16, Level 432
Anxiety/depression; Week 16, Level 501
Anxiety/depression; Week 24, Level 15450
Anxiety/depression; Week 24, Level 21715
Anxiety/depression; Week 24, Level 333
Anxiety/depression; Week 24, Level 412
Anxiety/depression; Week 24, Level 510
Anxiety/depression; Week 32, Level 14454
Anxiety/depression; Week 32, Level 22011
Anxiety/depression; Week 32, Level 332
Anxiety/depression; Week 32, Level 400
Anxiety/depression; Week 32, Level 520
SecondaryChange From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score at Weeks 2, 4, 8, 12, 16, 24, and 32

The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 32
Reported as:
Mean · scores on a scale
Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score at Weeks 2, 4, 8, 12, 16, 24, and 32
scores on a scaleRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Baseline74.21 ± 18.37373.93 ± 19.255
Change from Baseline at Week 28.85 ± 18.5444.05 ± 13.191
Change from Baseline at Week 410.73 ± 19.9045.38 ± 15.042
Change from Baseline at Week 810.75 ± 19.2926.92 ± 13.006
Change from Baseline at Week 1210.82 ± 20.5578.80 ± 13.343
Change from Baseline at Week 1610.97 ± 20.5677.67 ± 14.160
Change from Baseline at Week 2412.22 ± 21.22310.00 ± 12.444
Change from Baseline at Week 3212.34 ± 21.43011.95 ± 14.807
SecondaryChange From Baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up

The QOLHEQ is a validated disease-specific instrument to assess disease-specific health-related quality of life in participants suffering from CHE over the past 7 days. It consists of 30 items that are summarized according to impairments for 4 subscales: symptoms, emotions, limitations in functioning, and treatment and prevention. Each item is scored on a scale of never, rarely, sometimes, often, and all the time. The overall score is calculated by summing all items and ranges from 0 to 117. Higher scores indicate a greater impact on quality of life. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 36
Reported as:
Mean · scores on a scale
Change From Baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up
scores on a scaleRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
Baseline75.19 ± 23.86466.52 ± 23.224
Change from Baseline at Week 2-43.16 ± 24.337-21.98 ± 18.408
Change from Baseline at Week 4-50.22 ± 23.579-25.10 ± 21.021
Change from Baseline at Week 8-53.69 ± 25.377-28.44 ± 22.570
Change from Baseline at Week 12-55.00 ± 24.109-28.95 ± 24.322
Change from Baseline at Week 16-55.76 ± 26.741-29.56 ± 25.060
Change from Baseline at Week 24-54.97 ± 25.757-46.60 ± 24.862
Change from Baseline at Week 32-55.59 ± 23.885-50.04 ± 24.931
Change from Baseline at Safety Follow-up-48.07 ± 26.886-40.67 ± 27.454
SecondaryChange From Baseline in Work Productivity and Activity Impairment Questionnaire v2.0 in Chronic Hand Dermatitis (WPAI-ChHD) Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up

The WPAI-ChHD questionnaire is a patient-reported quantitative assessment of the amount of absenteeism (measured as percentage of work time missed \[PWTM\] due to CHE), presentism, and daily activity impairment (percentage of impairment while working \[PIWW\] due to CHE, percentage of overall work impairment \[POWI\] due to CHE, percentage of activity impairment \[PAI\] due to CHE) attributable to a specific health problem. The WPAI-ChHD is a 6-item questionnaire used to assess the impact of chronic hand dermatitis (ChHD, the same as CHE in this context) on job performance and productivity in the last 7 days. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Scores range from 0% (no impairment) to 100% (complete impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 36
Reported as:
Mean · percentage
Change From Baseline in Work Productivity and Activity Impairment Questionnaire v2.0 in Chronic Hand Dermatitis (WPAI-ChHD) Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up
percentageRuxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BID
PWTM, Baseline5.68 ± 16.5412.32 ± 7.736
PWTM, Change from Baseline at Week 2-4.90 ± 12.817-0.90 ± 5.858
PWTM, Change from Baseline at Week 4-3.15 ± 16.7340.82 ± 11.469
PWTM, Change from Baseline at Week 8-3.92 ± 19.3400.03 ± 11.714
PWTM, Change from Baseline at Week 12-0.72 ± 14.356-1.40 ± 9.591
PWTM, Change from Baseline at Week 16-0.57 ± 22.3980.06 ± 12.294
PWTM, Change from Baseline at Week 24-3.09 ± 12.916-0.36 ± 13.845
PWTM, Change from Baseline at Week 32-0.80 ± 16.359-0.83 ± 15.108
PWTM, Change from Baseline at Safety Follow-up-0.23 ± 9.681-0.67 ± 14.285
PIWW, Baseline46.52 ± 28.17138.82 ± 26.176
PIWW, Change from Baseline at Week 2-26.56 ± 26.888-12.22 ± 21.285
PIWW, Change from Baseline at Week 4-27.87 ± 28.642-13.87 ± 21.375
PIWW, Change from Baseline at Week 8-32.22 ± 25.365-13.00 ± 22.944
PIWW, Change from Baseline at Week 12-32.81 ± 27.500-11.72 ± 23.998
PIWW, Change from Baseline at Week 16-35.44 ± 28.162-14.33 ± 20.031
PIWW, Change from Baseline at Week 24-32.96 ± 27.584-28.52 ± 24.984
PIWW, Change from Baseline at Week 32-35.51 ± 26.775-30.21 ± 24.796
PIWW, Change from Baseline at Safety Follow-up-30.20 ± 30.672-21.67 ± 23.730
POWI, Baseline47.82 ± 28.06040.02 ± 26.651
POWI, Change from Baseline at Week 2-27.50 ± 26.315-10.85 ± 20.548
POWI, Change from Baseline at Week 4-25.78 ± 28.135-11.08 ± 22.539
POWI, Change from Baseline at Week 8-32.66 ± 25.633-10.82 ± 21.500
POWI, Change from Baseline at Week 12-32.55 ± 29.872-11.99 ± 25.552
POWI, Change from Baseline at Week 16-33.67 ± 30.196-14.10 ± 21.897
POWI, Change from Baseline at Week 24-33.95 ± 29.526-28.35 ± 29.678
POWI, Change from Baseline at Week 32-34.73 ± 28.130-29.59 ± 29.227
POWI, Change from Baseline at Safety Follow-up-29.88 ± 32.391-21.20 ± 26.726
PAI, Baseline56.40 ± 26.07949.45 ± 24.466
PAI, Change from Baseline at Week 2-30.37 ± 26.667-11.43 ± 21.236
PAI, Change from Baseline at Week 4-34.81 ± 26.651-16.71 ± 22.611
PAI, Change from Baseline at Week 8-36.25 ± 26.259-17.18 ± 24.169
PAI, Change from Baseline at Week 12-39.21 ± 26.671-20.13 ± 27.680
PAI, Change from Baseline at Week 16-41.07 ± 27.439-18.70 ± 22.381
PAI, Change from Baseline at Week 24-38.47 ± 27.304-35.71 ± 26.842
PAI, Change from Baseline at Week 32-39.12 ± 25.553-38.36 ± 25.382
PAI, Change from Baseline at Safety Follow-up-32.06 ± 27.782-26.27 ± 28.542
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE) in the DBVC Period

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) in the DBVC Period
ParticipantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) in the DBVC Period3629
SecondaryNumber of Participants With Any ≥Grade 3 TEAE in the DBVC Period

A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Any ≥Grade 3 TEAE in the DBVC Period
ParticipantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Number of Participants With Any ≥Grade 3 TEAE in the DBVC Period21
SecondaryNumber of Participants With Any TEAE in the OLE Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.

Time frame:
up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE in the OLE Period
ParticipantsOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Number of Participants With Any TEAE in the OLE Period1025
SecondaryNumber of Participants With Any ≥Grade 3 TEAE in the OLE Period

A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Any ≥Grade 3 TEAE in the OLE Period
ParticipantsOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Number of Participants With Any ≥Grade 3 TEAE in the OLE Period11
SecondaryNumber of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the DBVC Period

The investigator determined whether a change was clinically meaningful.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the DBVC Period
ParticipantsDouble-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BIDDBVC Period: Vehicle Cream BID
Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the DBVC Period00
SecondaryNumber of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the OLE Period

The investigator determined whether a change was clinically meaningful.

Time frame:
up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the OLE Period
ParticipantsOpen-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BIDOLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID
Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the OLE Period00

Adverse events

Collected over up to Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/92 (0%)1/92 (1.1%)9/92 (9.8%)
Ruxolitinib 1.5% Cream BID1/171 (0.6%)5/171 (2.9%)10/171 (5.8%)
Most frequent serious events
Most frequent serious events
EventVehicle Cream BIDRuxolitinib 1.5% Cream BID
Retinal artery embolismEye disorders1/920/171
Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/921/171
Cardiac arrestCardiac disorders0/921/171
OsteoarthritisMusculoskeletal and connective tissue disorders0/921/171
Prostatic obstructionReproductive system and breast disorders0/921/171
Sinus node dysfunctionCardiac disorders0/921/171
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib 1.5% Cream BID
NasopharyngitisInfections and infestations9/9210/171

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Mean47.8 ± 15.1148.1 ± 15.2948.0 ± 15.16
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Female5655111
Male383775
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BIDTotal
Hispanic or Latino6612
Not Hispanic or Latino8785172
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BIDVehicle Cream BID to Ruxolitinib 1.5% Cream BIDTotal
White/Caucasian8385168
Black/African American538
Asian527
Not Reported011
Indian101
Middle Eastern011
08

Study locations

36 sites
  • Southwest Skin Specialists Phoenix Biltmore
    Phoenix, Arizona 85018, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Marvel Clinical Research Llc
    Huntington Beach, California 92647, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Skin Research of South Florida, Llc
    Miami, Florida 33173, United States
  • Well Pharma Medical Research Corporation
    Miami, Florida 33173, United States
  • Forcare Clinical Research
    Tampa, Florida 33613, United States
  • Midwest Allergy Sinus Asthma, Sc
    Normal, Illinois 61761, United States
  • The Indiana Clinical Trials Center Ictc
    Plainfield, Indiana 46168, United States
  • Delricht Research
    Baton Rouge, Louisiana 70809, United States
  • Delricht Research
    New Orleans, Louisiana 70115, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48084, United States
  • Jubilee Clinical Research Inc
    Las Vegas, Nevada 89106, United States
  • Forest Hills Dermatology Group
    Kew Gardens, New York 11415, United States
  • Juva Skin and Laser Center
    New York, New York 10022, United States
  • Onsite Clinical Solutions, Llc Charlotte Central Office
    Charlotte, North Carolina 28277, United States
  • Bexley Dermatology
    Bexley, Ohio 43209, United States
  • Central Sooner Research
    Oklahoma City, Oklahoma 73118, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Austin Institute For Clinical Research Aicr Pflugerville
    Pflugerville, Texas 78660, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Dermatology Research Institute Inc.
    Calgary, Alberta T2J 7E1, Canada
  • Care Clinic
    Red Deer, Alberta T4P-1K4, Canada
  • Simcomed Health Ltd
    Barrie, Ontario L4M 1G7, Canada
  • Fachklinik Bad Bentheim Dermatologie
    Bad Bentheim, 48455, Germany
  • Derma-Study-Center Fn Gmbh
    Friedrichshafen, 88045, Germany
  • Dermatologische Gemeinschaftspraxis Mahlow
    Mahlow, 15831, Germany
  • Beldio Research Gmbh
    Memmingen, 87700, Germany
  • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. Z O.O.
    Elblag, 82-300, Poland
  • Centrum Badan Klinicznych Pi-House Sp. Z O.O.
    Gdansk, 80-546, Poland
  • Laser Clinic S.C.
    Szczecin, 70-332, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71-434, Poland
  • Klinika Ambroziak
    Warsaw, 02-953, Poland
  • Dermmedica Sp. Z O.O.
    Wroclaw, 51-318, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2024, 11 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Eczema, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 16. This study's 11 months is below that.

Counting every sponsor, half of 70 studies reached it within 14 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 18, 2023
StartActual
Jul 31, 2023
Primary completionActual
Jul 15, 2024
CompletionActual
Dec 13, 2024
Results first posted
Jul 31, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05906628
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jul 31, 2023
Primary completion
Jul 15, 2024
Completion
Dec 13, 2024
Results posted
Jul 31, 2025
Last update
Jul 31, 2025

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion